| Market Cap | ₹6,701.13 CrMid-range Performer |
|---|---|
| 1-Year Return | 305.71%Price Performance |
| TTM Net Profit | ₹161.19 Cr₹52.25 Cr Latest Qtr |
| P/E TTM | 41.57Sector PE 41.34 |
Key highlights
- UK MHRA grants marketing authorisation for Mesalazine 1g Suppositories
- Approval secured through wholly owned subsidiary Asterisk Lifesciences Ltd, UK
- Company reported a 91.75% YoY growth in net profit for the September 2026 quarter
- Follows earlier USFDA approval for the same product via a US partner in April 2025
- Management targets pharmaceutical revenue to reach 33.3% of group total by 2029
Strategic Entry Into the UK Pharmaceutical Market
Bliss GVS Pharma is accelerating its penetration into highly regulated global markets with the latest MHRA authorisation. The approval for Mesalazine 1g Suppositories, granted to its UK subsidiary Asterisk Lifesciences, establishes a direct commercial path in the United Kingdom. This regulatory milestone complements the company's existing international compliance record, which includes a WHO-GMP inspection closure for its Vevoor facility in June 2026 and an EU-GMP certificate from Romania's NAMMDR in November 2024.
By securing these approvals, the company is positioning itself to capture market share in specialized gastrointestinal treatments across Western geographies.
Regulatory Pipeline and Compliance Milestones
- Received final USFDA approval for Mesalamine Suppositories 1000 mg in April 2025 via partner Rising Pharma
- Vevoor manufacturing facility in Palghar confirmed GMP compliant by WHO in June 2026
- Operating profit margins surged to 25.72% in the September 2026 quarter from 13.0% a year earlier
- Group revenue target set to derive one-third of total income from pharmaceuticals within three years
- EU-GMP compliance achieved for manufacturing units in Palghar and Vevoor as of late 2024
Financial Performance and Growth Outlook
The MHRA approval coincides with a period of significant financial expansion for Bliss GVS Pharma. For the quarter ended September 30, 2026, the company reported a net profit of ₹52.25 crore, a 91.75% increase year-on-year. Quarterly revenue grew by 28.22% to ₹313.37 crore, significantly outperforming the broader sector's revenue growth of 16.62%.
With a trailing twelve-month operating revenue of ₹1,074.19 crore and a healthy Piotroski Score of 7, the company is leveraging its strengthened balance sheet to fund further regulatory filings and product launches in the suppository segment.
| Date | Announcement | Amount |
|---|---|---|
| 02 Jun 2026 | Received WHO-GMP Inspection Closure Report from the World Health Organization (WHO) confirming GMP compliance for the Vevoor manufacturing facility in Palghar, MaharashtraSource: NSE filing | – |
| 15 Apr 2025 | Granted final approval by the USFDA for the Abbreviated New Drug Application (ANDA) for Mesalamine Suppositories 1000 mg through US partner Rising Pharma Holdings, Inc.Source: NSE filing | – |
| 23 Nov 2024 | Received EU-GMP Certificate of Compliance from Romania's National Agency for Medicines and Medical Devices (NAMMDR) for manufacturing facilities in Palghar and VevoorSource: business-standard.com | – |
What to watch next
- Declaration of results for the appointment of Non-Executive Directors by November 17, 2026
- Shareholder voting results for the Senior Executive and Employee ESOP 2026 plans on November 30, 2026
- Update on commercial launch timelines for Mesalazine 1g Suppositories in the UK market
| Share price | ₹629.9 |
|---|---|
| Market capitalisation | ₹6,701.13 Cr |
| Revenue (annual) | ₹927.11 Cr |
| Net profit (annual) | ₹129.13 Cr |
| Revenue (latest quarter) | ₹313.37 Cr+9.73% vs previous quarter |
| Net profit (latest quarter) | ₹52.25 Cr+4.30% vs previous quarter |
| P/E (TTM) | 41.57×Sector 41.34× |
| Promoter holding | 50.07%+15.06% QoQ |
| FII holding | 5.03%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Bliss GVS Pharma Ltd announcing the grant of marketing authorisation from MHRA, UK. Market figures from a third-party data provider.
